Tadaki, Soichiro
Sakata, Yasuhiko
Miura, Yutaka
Nochioka, Kotaro
Miura, Masanobu
Miyata, Satoshi
Asakura, Masanori
Shimada, Kazunori
Yamamoto, Takeshi
Fukumoto, Yoshihiro
Kadokami, Toshiaki
Yasuda, Satoshi
Miura, Toshiro
Ando, Shin-ichi
Yano, Masafumi
Kitakaze, Masafumi
Daida, Hiroyuki
Shimokawa, Hiroaki
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (201412015B, 201120009B, 200825012B)
Japan Agency for Medical Research and Development (15ek0210043h0001)
Article History
Received: 23 April 2019
Accepted: 18 October 2019
First Online: 4 November 2019
Compliance with ethical standards
:
: The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine is supported in part by unrestricted research grants from Daiichi Sankyo Co., Ltd. (Tokyo, Japan), Bayer Yakuhin, Ltd. (Osaka, Japan), Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan), Kowa Pharmaceutical Co., Ltd. (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Dainippon Sumitomo Pharma, Co., Ltd. (Osaka, Japan), Nippon Boehringer Ingelheim Co., Ltd. (Tokyo, Japan), Astellas Pharma (Tokyo, Japan), AstraZeneca (Osaka, Japan), Chugai Pharmaceutical (Tokyo, Japan), GlaxoSmithKline (Tokyo, Japan), Mitsubishi Tanabe Pharma (Osaka, Japan), Mochida Pharmaceutical (Tokyo, Japan), MSD (Tokyo, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Shionogi (Osaka, Japan) and Takeda Pharmaceutical (Tokyo, Japan). H.S. has received lecture fees from Bayer Yakuhin, Ltd. (Osaka, Japan), Daiichi Sankyo Co., Ltd. (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan).